Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Fri Dec 15 17:32:53 GMT 2023
by
admin
on
Fri Dec 15 17:32:53 GMT 2023
|
Protein Type | MONOCLONAL ANTIBODY |
Protein Sub Type | IGG1 |
Sequence Origin | MOUSE CHIMERIC |
Sequence Type | COMPLETE |
Record UNII |
4F4X42SYQ6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type |
---|
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
MABTHERA (AUTHORIZED: ARTHRITIS, RHEUMATOID)
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
MABTHERA (AUTHORIZED: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL)
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
177603
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
923822
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
NDF-RT |
N0000175078
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
781520
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
465014
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
840621
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
542416
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
WHO-VATC |
QL01XC02
Created by
admin on Fri Dec 15 17:32:54 GMT 2023 , Edited by admin on Fri Dec 15 17:32:54 GMT 2023
|
||
|
NCI_THESAURUS |
C129822
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
MABTHERA (AUTHORIZED: LYMPHOMA, NON-HODGKIN)
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
79793
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
546516
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
LIVERTOX |
NBK548249
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
922222
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
216305
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
NCI_THESAURUS |
C141215
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
NDF-RT |
N0000175657
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
155102
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
545616
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
WHO-ATC |
L01XC02
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
529816
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/17/1869
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6780
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
PRIMARY | |||
|
m9637
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000089292
Created by
admin on Fri Dec 15 17:32:54 GMT 2023 , Edited by admin on Fri Dec 15 17:32:54 GMT 2023
|
PRIMARY | |||
|
DB00073
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
PRIMARY | |||
|
2273510
Created by
admin on Fri Dec 15 17:32:54 GMT 2023 , Edited by admin on Fri Dec 15 17:32:54 GMT 2023
|
ALTERNATIVE | |||
|
RITUXAN
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
PRIMARY | APPROVED AUGUST 2014 | ||
|
4F4X42SYQ6
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201576
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
PRIMARY | |||
|
RITUXIMAB
Created by
admin on Fri Dec 15 17:32:54 GMT 2023 , Edited by admin on Fri Dec 15 17:32:54 GMT 2023
|
PRIMARY | |||
|
II-64
Created by
admin on Fri Dec 15 17:32:54 GMT 2023 , Edited by admin on Fri Dec 15 17:32:54 GMT 2023
|
PRIMARY | |||
|
1445539
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
PRIMARY | |||
|
C1702
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
PRIMARY | |||
|
7609
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
PRIMARY | |||
|
174722-31-7
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
PRIMARY | |||
|
121191
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB12570MIG
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
PRIMARY | |||
|
C092560
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
PRIMARY | |||
|
Rituximab
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
PRIMARY | |||
|
DTXSID5040910
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
PRIMARY | |||
|
4F4X42SYQ6
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
PRIMARY | |||
|
2105824
Created by
admin on Fri Dec 15 17:32:54 GMT 2023 , Edited by admin on Fri Dec 15 17:32:54 GMT 2023
|
ALTERNATIVE | |||
|
4975
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
PRIMARY | |||
|
ROMIPLATE
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
PRIMARY | APPROVED JANUARY 2011 | ||
|
7455
Created by
admin on Fri Dec 15 17:32:53 GMT 2023 , Edited by admin on Fri Dec 15 17:32:53 GMT 2023
|
PRIMARY |
From | To |
---|---|
1_22 | 1_96 |
1_148 | 1_204 |
1_265 | 1_325 |
1_371 | 1_429 |
3_23 | 3_87 |
3_133 | 4_193 |
2_224 | 3_213 |
2_22 | 2_96 |
2_148 | 2_204 |
2_265 | 2_325 |
2_371 | 2_429 |
3_23 | 3_87 |
3_133 | 4_193 |
2_224 | 3_213 |
1_230 | 2_230 |
1_233 | 2_233 |
Glycosylation Type | MAMMALIAN |
Glycosylation Link Type | Site |
---|---|
N | 1_301 |
N | 2_301 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BIOSIMILAR -> PARENT |
|
||
|
SUB_CONCEPT->SUBSTANCE | |||
|
BIOSIMILAR -> PARENT |
|
||
|
SUB_CONCEPT->SUBSTANCE |
|
||
|
TARGET -> INHIBITOR | |||
|
BIOSIMILAR -> PARENT |
|
||
|
LABELED -> NON-LABELED | |||
|
SUB_CONCEPT->SUBSTANCE |
|
||
|
TARGET -> SUBSTRATE | |||
|
TARGET->LIGAND |
BINDING
|
||
|
TARGET -> AGONIST | |||
|
SUB_CONCEPT->SUBSTANCE |
|
||
|
SUB_CONCEPT->SUBSTANCE |
|
||
|
SUB_CONCEPT->SUBSTANCE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Molecular Formula | CHEMICAL |
|
||||
MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|